Spyre Therapeutics Inc (SYRE)

R&D Expense Growth

8.43%

Quarterly · Period ending:

SYRE logo

SYRE R&D Expense Growth

Latest reported8.43%
SYRE Quarterly R&D Growth (QoQ) (0.00% → 8.43%)
High-resolution chart · PNG

SYRE r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Spyre Therapeutics Inc R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
8.4289%
35.3354%
-1.3459%
12.7089%
-3.5509%
-17.5488%
12.8241%
37.1001%
-6.5621%
3.6993%
36.5856%
41.8383%
26.205%
-3.3331%
18.9864%
-22.0907%
-9.4534%
1.1679%
12.9873%
9.3821%
14.5424%
-24.7588%
26.5441%
-26.1901%
15.8426%
-17.1012%
-1.5304%
20.4849%
2.898%
21.9613%
32.1313%
-2.1158%
32.7802%
18.6324%
-7.1806%
6.9237%
17.9026%
4.3873%
-11.9591%
21.8326%
22.9143%
-9.3293%
26.7498%
14.364%
68.6806%
-36.4669%
2.6538%
97.852%
135.8349%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.